212 related articles for article (PubMed ID: 35807227)
1. Discovery of Phenylcarbamoylazinane-1,2,4-Triazole Amides Derivatives as the Potential Inhibitors of Aldo-Keto Reductases (AKR1B1 & AKRB10): Potential Lead Molecules for Treatment of Colon Cancer.
Saeed A; Ejaz SA; Sarfraz M; Tamam N; Siddique F; Riaz N; Qais FA; Chtita S; Iqbal J
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807227
[TBL] [Abstract][Full Text] [Related]
2. Repurposing of Strychnine as the Potential Inhibitors of Aldo-keto Reductase Family 1 Members B1 and B10: Computational Modeling and Pharmacokinetic Analysis.
Sarfraz M; Aziz M; Afzal S; Channar PA; Alsfouk BA; Kandhro GA; Hassan S; Sultan A; Hamad A; Arafat M; Qaiser MN; Ahmed A; Siddique F; Ejaz SA
Protein J; 2024 Apr; 43(2):207-224. PubMed ID: 37940790
[TBL] [Abstract][Full Text] [Related]
3. In-silico Investigations of quinine and quinidine as potential Inhibitors of AKR1B1 and AKR1B10: Functional and structural characterization.
Ejaz SA; Saeed A; Birmani PR; Katubi KM; Elqahtani ZM; Al-Buriahi MS; Ujan R; Siddique F; Ahmed SB; Alrowaili ZA
PLoS One; 2022; 17(10):e0271602. PubMed ID: 36301939
[TBL] [Abstract][Full Text] [Related]
4. New Insight into the Pharmacological Importance of Atropine as the Potential Inhibitor of AKR1B1 via Detailed Computational Investigations: DFTs, ADMET, Molecular Docking, and Molecular Dynamics Studies.
Ejaz SA; Aziz M; Ahmed A; Alotaibi SS; Albogami SM; Siddique F; Batiha GE
Appl Biochem Biotechnol; 2023 Aug; 195(8):5136-5157. PubMed ID: 36847982
[TBL] [Abstract][Full Text] [Related]
5. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
7. Molecular hybrids of substituted phenylcarbamoylpiperidine and 1,2,4-triazole methylacetamide as potent 15-LOX inhibitors: Design, synthesis, DFT calculations and molecular docking studies.
Nawaz Z; Riaz N; Saleem M; Iqbal A; Abida Ejaz S; Bashir B; Muzaffar S; Ashraf M; Aziz-Ur-Rehman ; Sajjad Bilal M; Krishna Prabhala B; Sajid S
Bioorg Chem; 2024 Feb; 143():106984. PubMed ID: 38056389
[TBL] [Abstract][Full Text] [Related]
8. Decoding selectivity: computational insights into AKR1B1 and AKR1B10 inhibition.
Liu M; Qin X; Li J; Jiang Y; Jiang J; Guo J; Xu H; Wang Y; Bi H; Wang Z
Phys Chem Chem Phys; 2024 Mar; 26(12):9295-9308. PubMed ID: 38469695
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive computational approach for the identification of structure-based potential pharmacological candidates as selective AKR1B1 and AKR1B10 inhibitors: repurposing of purine alkaloids for the treatment of cancer.
Aziz M; Ejaz SA; Tamam N; Siddique F
J Biomol Struct Dyn; 2023; 41(16):7892-7912. PubMed ID: 36214620
[TBL] [Abstract][Full Text] [Related]
10. Investigations of
Bashir B; Riaz N; Ejaz SA; Saleem M; Iqbal A; Ashraf M; Ejaz S; -Rehman AU; Aziz M; Bhattarai K
J Biomol Struct Dyn; 2023; 41(24):15549-15568. PubMed ID: 36946200
[TBL] [Abstract][Full Text] [Related]
11. Probing phenylcarbamoylazinane-1,2,4-triazole amides derivatives as lipoxygenase inhibitors along with cytotoxic, ADME and molecular docking studies.
Muzaffar S; Shahid W; Riaz N; Saleem M; Ashraf M; Aziz-Ur-Rehman ; Bashir B; Kaleem A; Al-Rashida M; Baral B; Bhattarai K; Gross H
Bioorg Chem; 2021 Feb; 107():104525. PubMed ID: 33317840
[TBL] [Abstract][Full Text] [Related]
12. Identification of potent inhibitors of NEK7 protein using a comprehensive computational approach.
Aziz M; Ejaz SA; Tamam N; Siddique F; Riaz N; Qais FA; Chtita S; Iqbal J
Sci Rep; 2022 Apr; 12(1):6404. PubMed ID: 35436996
[TBL] [Abstract][Full Text] [Related]
13. The hop-derived compounds xanthohumol, isoxanthohumol and 8-prenylnaringenin are tight-binding inhibitors of human aldo-keto reductases 1B1 and 1B10.
Seliger JM; Misuri L; Maser E; Hintzpeter J
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):607-614. PubMed ID: 29532688
[TBL] [Abstract][Full Text] [Related]
14. Engineering aldo-keto reductase 1B10 to mimic the distinct 1B15 topology and specificity towards inhibitors and substrates, including retinoids and steroids.
Giménez-Dejoz J; Weber S; Fernández-Pardo Á; Möller G; Adamski J; Porté S; Parés X; Farrés J
Chem Biol Interact; 2019 Jul; 307():186-194. PubMed ID: 31028727
[TBL] [Abstract][Full Text] [Related]
15. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
[TBL] [Abstract][Full Text] [Related]
16. Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.
Kikuya M; Furuichi K; Hirao T; Endo S; Toyooka N; Ito K; Aoki S
J Pharmacol Sci; 2021 Sep; 147(1):1-8. PubMed ID: 34294359
[TBL] [Abstract][Full Text] [Related]
17. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
18. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer.
Taskoparan B; Seza EG; Demirkol S; Tuncer S; Stefek M; Gure AO; Banerjee S
Cell Oncol (Dordr); 2017 Dec; 40(6):563-578. PubMed ID: 28929377
[TBL] [Abstract][Full Text] [Related]
19. AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer.
Hojnik M; Šuster NK; Smrkolj Š; Sisinger D; Grazio SF; Verdenik I; Rižner TL
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159076
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway.
Demirkol Canlı S; Seza EG; Sheraj I; Gömçeli I; Turhan N; Carberry S; Prehn JHM; Güre AO; Banerjee S
Carcinogenesis; 2020 Sep; 41(9):1219-1228. PubMed ID: 32628753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
